NL-OMON55753招募中不适用
Vedolizumab in PSC and concurrent IBD: Searching for the missing link between the gut and the liver and exploration of biomarkers for development of colorectal carcinoma. - VIP study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Diagnosis of Primary Sclerosing Cholangitis and concommitant diagnosis of
- •Inflammatory bowel disease, Group 2:
- •- Diagnosis of inflammatory bowel disease
- •- 10 patients with routine vedolizumab treatment, 10 patients without
- •vedolizumab treatment , Both groups:
- •- Age 18 years and older, either male or female
- •- Ability to give informed consent
- •- Groups will be stratified for the use of thiopurines
- •- Groups will be stratified for UC, CD and IBDU
排除标准
- •- Medical history of proctocolectomy
- •- Use of biologic therapy other than vedolizumab within 8 weeks of enrolment
- •- Inability to give informed consent
研究者
相似试验
招募中
不适用
Biomarkers voor darmkamer bij patiënten met Primair Scleroserende Cholangitis en een inflammatoire darmziekte: de VIP studieNL-OMON26884Academic Medical Center (AMC), Amsterdam40
已完成
不适用
Vedolizumab Study with Inflammatory Bowel Disease Patients in GermanyK50K51Crohn disease [regional enteritis]Ulcerative colitisDRKS00013251CED Service GmbH1,280
已完成
不适用
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World PracticeInflammatory Bowel DiseasesCrohns DiseaseColitis, UlcerativeNCT04890262Takeda99
招募中
4 期
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.Crohn's DiseaseNCT06180382Centre Hospitalier Universitaire de Saint Etienne220
已完成
1 期
Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD PatientsColitis, UlcerativeCrohn DiseaseNCT04112212University Medical Center Groningen38